CXCL8 and cancer: CXCR1/2 are highly expressed by neutrophils, and guide them to their dominant ligand IL8 and alternate ligands (CXCL1, CXCL2, CXCL5, and CXCL6) that are elevated in many cancers and regulated by various factors in the TME (as reviewed in [128]).